1 May 2026Oral drugs
Cabergoline oral
Cabergoline guidance for inhibition or suppression of lactation after fetal or neonatal loss, with postpartum safety restrictions.
Prescription under medical supervision
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.
Therapeutic action
Long-lasting lactation inhibitor.
Indications
Inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death.
Forms and strengths
- 0.5 mg scored tablet.
Dose and duration
Lactation inhibition
- 1 mg single dose on the first day post-partum.
Lactation suppression
- 0.25 mg every 12 hours for 2 days.
Contra-indications, adverse effects, precautions
- Do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, or a history of pulmonary, retroperitoneal, or pericardial fibrosis.
- May cause hypotension, valvulopathy, dizziness, headache, nausea, drowsiness, and hallucinations.
- Do not combine with chlorpromazine, haloperidol, metoclopramide, or promethazine because the effect of cabergoline is antagonised.
- Do not combine with methylergometrine because of the risk of vasoconstriction and hypertensive crisis.
- Do not combine with macrolides because the effect of cabergoline is increased.
- Pregnancy: contraindicated.
Source
MSF Essential drugs practical guidelines (January 2026)
This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.
Rate this guide
Be the first to rate this guide.